Shots:
- Harbour BioMed has entered into a strategic collaboration with Insilico Medicine to accelerate therapeutic antibody development, combining their expertise in antibody discovery and artificial intelligence
- The companies will also collaborate on early-stage drug discovery targeting novel antibodies, leveraging Insilico’s AI expertise and Harbour BioMed’s wet lab capabilities for immunology, oncology, and neuroscience, aiming to address unmet medical needs
- Since 2021, the company has built a pipeline of 30 assets using its Pharma.AI platform, with 10 receiving IND clearance, setting a benchmark for AI-driven drug discovery. In July 2024, Insilico launched Generative Biologics, an AI tool for de novo protein engineering to speed up biologics development
Ref: Harbour BioMed | Image: Harbour BioMed & Insilico Medicine
Related News:- Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
